secwatch.observer — SEC 8-K summary
======================================

Issuer:     Serina Therapeutics, Inc. (SER)
CIK:        0001708599
Form:       8-K
Filed at:   2026-09-09T11:43:19+00:00
Accession:  0001708599-26-000054
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Serina's SER-252 Phase 1b Cohort 1 clears safety review; advances to Cohort 2
-----------------------------------------------------------------------------

- Independent Safety Monitoring Committee recommended advancing SER-252 to Cohort 2 after blinded review of Cohort 1 safety/tolerability data.
- Cohort 1 (lowest dose, n=8) showed sustained apomorphine exposure and motor function improvements in individual patients.
- Topline data from single-ascending-dose portion expected in first half of 2027.
- Study is randomized, double-blind, placebo-controlled; 5 cohorts of 8 in SAD portion, then MAD portion.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1708599/000170859926000054/0001708599-26-000054-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1708599/000170859926000054/ser-20260909.htm
  HTML page:      https://secwatch.observer/filing/0001708599-26-000054

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer